2036272-55-4

Basic information

• Product Name: 1,2-distearoyl-sn-glycero-3-phosphocholine
• CAS NO: 2036272-55-4
• Molecular Weight: 766.286
• Mol File: 2036272-55-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,2-distearoyl-sn-glycero-3-phosphocholine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-distearoyl-sn-glycero-3-phosphocholine(2036272-55-4)
• EPA Substance Registry System: 1,2-distearoyl-sn-glycero-3-phosphocholine(2036272-55-4)

Safety Data

• Hazardous Substances Data: 2036272-55-4(Hazardous Substances Data)

Usage

Chemical structure

DSPC is a phospholipid molecule consisting of a glycerol backbone, two stearic acid chains, and a phosphate head group.

Stability

DSPC is known for its ability to form stable and rigid bilayer structures.

Drug encapsulation

Due to its stable bilayer structure, DSPC is ideal for encapsulating drugs and protecting them from degradation in the body.

Liposomal drug delivery systems

DSPC is commonly used in the formulation of liposomal drug delivery systems.

Therapeutic applications

DSPC has been studied for its potential therapeutic applications in treating lung diseases and cancer.

Versatility

DSPC is a versatile chemical used in the field of pharmaceuticals and biotechnology.

Molecular weight

734.07 g/mol (DSPC has a molecular weight of approximately 734.07 grams per mole).

Physical state

DSPC is a solid at room temperature and melts at a temperature of around 55°C (131°F).

Upstream product

• 25354-97-6 2-hexyldecanoic acid 
• 13325-10-5 4-Aminobutanol 
• 1849616-54-1 6-oxohexyl 2-hexyldecanoate 
• 74918-57-3 2-hexyldecanoic acid chloride 
• 629-11-8 1,6-hexanediol 

Relevant articles and documents

LIPID NANOPARTICLE MRNA VACCINES

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE

A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE

The present invention relates to compositions and methods for inducing adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.